Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option ...

IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in larger, higher-risk polyps.REC-4881 shows ...
CNN

Recursion Pharmaceuticals, Inc. Class A

RXRX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.20 since the market last closed. This is a 4.96% ...